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ABSTRACT
Original Article
Background and Objectives
Gaucher disease type I can be successfully treated with enzyme replacement thera-
py (ERT). In order to reduce the burden of the intravenously administered enzyme, a
low frequency of administration was prospectively studied in patients with stable and
minor disease following ERT. 
Design and Methods
Eleven patients were randomly assigned either to continue their original regimen of a
dose of ERT once every week or fortnight (five patients) or to lower the frequency of
administration to once every 4 weeks, at the same cumulative dose (six patients). The
primary end-point was change in liver ratio (mL/kg body weight). Secondary end-points
were spleen volume, hemoglobin level, platelet count, lumbar bone marrow fat con-
tent measured with quantitative chemical shift imaging (QCSI), white cell count, and
plasma levels of ferritin, chitotriosidase, liver enzymes and angiotensin-converting
enzyme (ACE). 
Results
There were no significant mean differences between the two treatment arms in liver
ratio or any of the other end-points. However, there were two treatment failures in the
low frequency of administration group. These patients showed progression of disease
as evidenced by a reduction of QCSI in one patient and an increase in liver ratio as
well as a slow decrease in QCSI in the other. Both patients already had relatively low
baseline QCSI values. One patient switched back to the original regimen at 6 months
because of subjective complaints.
Interpretation and Conclusions
Low frequency ERT in adult Gaucher type I patients maintains stable disease in most,
but not all patients with stable and minimal disease. Close monitoring of all disease
parameters remains mandatory.
Key words: Gaucher disease, anemia, thrombocytopenia,
randomized trial.
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Gaucher disease type I is the most common lysoso-mal storage disorder. Deficiency of the lysosomalenzyme glucocerebrosidase (OMIM #230800)
leads to the accumulation of glucocerebroside in spleen,
liver and bone marrow.1,2 In the early 1990s, Gaucher dis-
ease was the first of the lysosomal storage disorders treat-
ed successfully with enzyme replacement therapy (ERT),
using intravenous mannose-terminated enzyme from pla-
cental tissue (alglucerase) or recombinant enzyme (imi -
glucerase), both manufactured by Genzyme Corp oration
(MA, USA). Most  patients respond to treatment, with
normalization of blood counts, a reduction in liver and
spleen size and improvement in bone symptoms.3-10
Dosing schedules may vary with frequencies of adminis-
tration ranging from three times a week up to once every
2 weeks. At some point after starting ERT, many patients
become stable with minimal residual symptoms.
Reducing the frequency of treatment to once every 4
weeks might improve their quality of life. In one study,
low frequency maintenance therapy was considered
unsuccessful, but the patients  exhibited significant resid-
ual disease at the time of switching to low frequency
administration and the maintenance regimen was given at
a reduced cumulative dose.11 No randomized controlled
prospective trials aimed at lengthening the dose interval
have been reported. The aim of the present study was to
evaluate whether stable disease could be maintained with
a less burdensome schedule of ERT of once every 4 weeks
at an equal cumulative dose in patients with stable and
minimal residual Gaucher disease after a minimum of 2
years of ERT.
Design and Methods
The protocol was approved by the Academic Medical
Center institutional review board. All patients gave writ-
ten informed consent. 
Eligibility criteria
In order to be eligible for the study, patients had to be
older than 18 years and have proven Gaucher type I dis-
ease, as evidenced by physical and neurological evalua-
tion and documentation of deficient glucocerebrosidase
activity in leukocytes12 and genotyping.13 They also had to
have received enzyme therapy according to our national
protocol6 for at least 2 years prior to study enrolment.
Finally, they had to have mild, stable Gaucher disease,
defined by having all of the following throughout the 24
months prior to screening: 
(i) hemoglobin levels within normal limits (male > 12.8
g/dL, female >12.0 g/dL); 
(ii) platelet count > 100x109/L; 
(iii) no or asymptomatic organomegaly; 
(iv) no significant bone complications, such as a vascular
necrosis, pathologic fractures, orthopedic replacement or
bone-crises;  
(v) lumbar marrow fat content >23% measured by
quantitative chemical shift imaging (QCSI);  
(vi) a maximum variability of 30% in plasma chi-
totriosidase levels.
Randomization
Block randomization was used to assign patients to
receive infusions either once every 4 weeks (low frequen-
cy group) or to continue their original schedule (once
every 1 or 2 weeks, control group). The total monthly
dose remained unchanged. Patients remained on study for
12 months or until study withdrawal. 
Data collection
Baseline data on sex, age, body weight, splenectomy,
severity score index (SSI),14 dosing and genotype were
recorded. Interviews, physical examination and investiga-
tions at the outpatient clinic took place at months 0, 2, 4,
6, 9 and 12. Follow-up parameters included white cell
count, hemoglobin, platelet count, ferritin, alkaline phos-
phatase, alanine transaminase (ALT), aspartate transami-
nase (AST), gammaglutamyl transferase (γ-GT), lactate
dehydrogenase (LDH), angiotensin-converting enzyme
(ACE), chitotriosidase (performed by standard enzyme
activity assay with 4 MU chitotriose (Sigma, St. Louis,
MO, USA) as a substrate at pH 5.2)15 and hexosaminidase
(using 4-methylumbelliferyl-N-acetylglucosamine (Sigma),
as a substrate in citrate/phosphate buffer (0.1/0.2 M) at pH
4.0) at months 0, 2, 4, 6, 9 and 12. Chitotriosidase values
of patients who were heterozygous for the chitotriosidase
mutation were multiplied by two.16,17 At months 0, 6 and
12 liver and spleen volumes were measured by spiral com-
puted axial tomography, a method that has a reported
accuracy of 3-5%.18-20 To correct for changes in body
weight, the liver ratio was calculated (liver volume/body
weight [mL/kg]). The spleen ratio was not calculated,
since spleen volume in adults is not influenced by changes
in body weight. Bone marrow involvement was assessed
by measurement of the bone marrow fat fraction using
Dixon’s QCSI of the lumbar spine21,22 and clinical bone dis-
ease was assessed at each study visit. 
Analysis of efficacy (two methods)
Overall outcome
Stability of the liver ratio was the primary endpoint.
Secondary end-points were stability of chitotriosidase,
hemoglobin, platelet count, hexosaminidase, spleen vol-
ume, QCSI, AST, ALT, γ-GT, LDH, alkaline phosphatase,
ACE and ferritin. The sample size was determined based
on a required power of 90% and an α of 10%. It was esti-
mated that a difference in liver ratio of 9% in 1 year
between the two treatment arms could be excluded using
six patients in each group. Differences in baseline charac-
teristics between the low frequency group and the control
group and between patients in the low frequency group
with stable disease and those in whom treatment failed
were evaluated by the Mann-Whitney U test or the χ2
test. Relative changes of follow-up parameters compared
to to baseline values were analyzed by the Mann-
Whitney U test. Correlations between the relative
changes of the follow-up parameters were determined
using Spearman’s ρ test.
Individual patient outcomes
Outcomes were assessed using criteria for disease pro-
gression, based on prior data of variability in 18 patients
with clinically stable disease, defined as an unchanged
maintenance dose of Cerezyme for at least 2 years.  In
these patients the standard deviation for percentage
variability of chitotriosidase activity, liver ratio, spleen
volume and QCSI were 12.5%, 3.9%, 4.4% and 4.1%,
respectively. Disease progression was defined as any
one of:
(i) an increase in liver ratio of > 10% from baseline or 
an enlarged liver (>25 mL/kg);
(ii) an increase in chitotriosidase level by ≥30% from
baseline in two consecutive laboratory evaluations
(extra monitoring was performed within 1 month in the
case of a >15% increase); 
(iii) a decrease in QCSI to ≤23%; 
(iv) the occurrence of avascular necrosis, pathologic
fractures or bone-crises; 
OR two of the following:
(i) an increase from baseline in spleen volume of > 10%; 
(ii) a reduction in hemoglobin level to <12.8 g/dL
(males) or 12.0 g/dL (females) at two consecutive labora-
tory evaluations (performed within 1 month of each
other);
(iii) a reduction in platelet count to <100x109/L at two
consecutive laboratory evaluations (performed within 1
month of each other.)
(iv) a relative decrease in QCSI of ≥20% from baseline
at two consecutive evaluations. 
Treatment was considered to have failed if patients
showed manifestations of disease progression according
to these criteria. Patients in the low frequency group in
whom treatment failed were reverted to their original dos-
ing frequency and followed closely for improvement.
Results
Of the 53 patients in our institution who were treat-
ed with ERT, 12 fulfilled the entry criteria. One patient
was not willing to participate in the study. The baseline
characteristics of the 11 patients who were enrolled in
the study are shown in Table 1. These 11 patients were
randomly assigned to continue their original high fre-
quency dosing schedule (once every week, patients n. 1,
3, 4 and 5, or once every 2 weeks, patient n. 2) or to
receive the same monthly dose at a frequency of once
every 4 weeks (patients n. 6-11). Both groups were
genetically identical; one patient in the low frequency
group was homozygous for the N370S mutation and all
others were compound heterozygotes for N370S and
L444P or another mutation. 
The control group had slightly milder disease as indi-
cated by the presence of smaller spleens (p=0.02),
absence of patients with splenectomy, a slightly lower
SSI (p=0.05) and lower liver ratio’s (p=0.05) as compared
to the low frequency group. Also, the monthly dose of
ERT was approximately 50% lower in the control group
(p=0.03). The total cumulative dose and the number of
years of having received ERT were comparable p=0.247
and p=0.792, respectively). Two patients (#6 and 8)
were heterozygous for the chitotriosidase mutation:
their chitotriosidase levels were multiplied by two.
None was chitotriosidase deficient. 
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Table 1. Characteristics of the 11 patients included in the study. 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
1 H M 53 0 N370S/L444P 15,4 160 19 440 56 4175 1244 15 4 9 1575 4 24415
2 H F 66 1 N370S/L444P 13,3 137 21 230 53 2173 1183 15 2 11 2070 4 9262
3 H F 55 4 N370S/R120W 14,1 151 20 446 32 5184 854 18 4 12 4152 6 30583
4 H F 58 1 N370S/L444P 13,1 161 26 231 52 9068 1222 15 4 10 1800 7 23084
5 H M 48 2 N370S/L444P 15,5 192 18 303 50 133 1038 15 4 9 1695 4 7387
6 L M 39 4 N370S/N370S 14,9 307 21 Sx 65 5744 1223 30 4 3 1170 6 40184
7 L M 43 3 N370S/IVS2+1 14,6 122 25 1093 29 6229 926 50 2 12 6835 7 26082
8 L M 56 3 N370S/L444P 13,8 180 32 613 43 5082 1233 30 4 9 3120 5 25706
9 L F 34 5 N370S/L444P 13,8 261 31 Sx 33 3056 1382 30 4 3 1110 8 19363
10 L F 75 4N370S/RECNCIL 14,8 129 23 862 55 3410 1288 15 2 10 3540 8 16703
11 L M 38 3 N370S/L444P 15,5 99 24 1111 38 8338 1236 40 4 8 3540 5 45211
1: Patient n.; 2: high/low frequency; 3: gender; 4: age; 5: SSI; 6: genotype; 7: Hb (g/dL); 8: platelet count (x109/L); 9: Liver ratio (mL/kg); 10: Spleen volume (mL);
11: QCSI (%); 12: Chitotriosidase (nmol/mL.hr); 13: Hexosaminidase (nmol/mL.hr); 14: Dose (U/kg/4weeks); 15: Original frequency (x/4 weeks); 16: No. of years on
ERT; 17: cumulative dose since starting ERT (U/kg); 18: SSI before starting ERT; 19: Chitotriosidase (nmol/ml.hr) before starting ERT. Chitotriosidase levels of patients
who were heterozygous for the chitotriosidase mutation (patients #6 and 8) were multiplied by two. H: high frequency (ERT once every 1-2 weeks); L: low frequency
(ERT once every 4 weeks); M: male; F: female; SSI: Severity Score Index (21); Sx: splenectomy; QCSI:  Quantative chemical shift imaging. 
Overall outcome
There were no differences in the mean percentage
change from baseline at 12 months in liver ratio
between the low frequency group and the control group
(mean percentage±SD: 102.0±5.0 in the control group vs
98.1±10.1 in the low frequency group, p=0.329, Figure
1A). Likewise, the mean changes in the secondary
parameters (spleen volume, hemoglobin level, platelet
count, chitotriosidase, QCSI, white cell count, ferritin,
liver enzymes and ACE) did not show significant differ-
ences between the low frequency group and the control
group. No bone complications occurred during the
study period in either group.   
No strong correlations (i.e. ρ>0.6) were found
between the relative changes of the different parame-
ters, except for change in liver and spleen volume
(ρ=0.632, p=0.004). 
Individual outcomes
Treatment was not considered to have failed in any of
Figure 1A-F. Percentage changes in liver ratio (A) and spleen volume (B), absolute changes in hemoglobin (C) and platelet count (D), and
percentage changes in chitotriosidase (E), and QCSI (F). Patients from the high frequency group (ERT once every 1-2weeks) are repre-
sented in red; patients from the low frequency group (ERT once every 4 weeks) are represented in black. 
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the patients in the control group. Two patients (#7 and
9) from the low frequency group met the protocol crite-
ria for treatment failure. Prior to randomization to low
frequency treatment, these patients differed from the
others in this group only with respect to a baseline fat
fraction of <35%. Patient #10 withdrew from the study
at 6 months because of persisting subjective complaints.
The three patients who continued the once every 4
weeks schedule considered the new regimen an impor-
tant improvement that made them feel less restricted in
their free time, although one patient was dissatisfied
with the longer dose-related duration of the infusion. 
Control group
Patients #1, 4 and 5 remained stable. Patient #2
showed an increase in spleen volume of >10% at 6
months and also an increase in chitotriosidase of >30%
at a single measurement, which was not confirmed by a
second analysis. Although this patient had a relative
increase of 11% in the liver ratio the ratio remained
within the normal range (<25 mL/kg). Thus, the criteria
for treatment failure were not met. No explanation (e.g.
infection, non-compliance) was found for the tempo-
rary deterioration. Patient #3 showed an increase in chi-
totriosidase including one value that increased  >30% of
baseline, but was again not confirmed in a second
analysis. Other parameters remained stable. Also in this
patient, there was no indication of non-compliance. 
Low frequency group
The disease parameters of patient n. 6 remained sta-
ble. After completion of the study the low frequency
regimen was continued. Patient n. 7 showed a decrease
in QCSI from 29% at baseline to 24% at 12 months (rel-
ative decrease of 17%), without clinical bone problems.
The liver ratio increased by 12% and he complained of
fatigue and abdominal discomfort. The criteria for treat-
ment failure were met and at 12 months the patient
returned to his original dosing regimen of once every 2
weeks. Six months after the switch the QCSI had
increased to 26% but tiredness persisted. 
Patient n. 8 had an increase in spleen volume of >10%
with a single hemoglobin value below the normal range.
His chitotriosidase levels tended to increase, but by less
than 30% (maximum 22% at 12 months). The QCSI
remained stable. This patient possibly suffered from an
intercurrent infection although serological tests and
polymerase chain reaction analysis gave no indication
of a recent Epstein-Barr virus or cytomegalovirus infec-
tion. He continued the low frequency regimen.
Chitotriosidase, spleen volume and hemoglobin con-
centration recovered quickly. Patient n. 9 had a decrease
in QCSI from 33% to 23% in 12 months, without bone
complications or complaints. Other parameters did not
change significantly. Following protocol she returned to
her previous high frequency regimen, after which QCSI
increased to 27% (at 18 months). 
Patient #10 showed an increase in splenomegaly of
11% from baseline at 6 months. Before starting the
study this patient had suffered from chronic bone and
muscle pain which continued throughout the study.
Magnetic resonance imaging of the upper leg indicated
a possible myositis. Biopsy was refused and the diagno-
sis could not be confirmed. The patient chose to return
to the higher frequency dosing regimen after 6 months
because of uncertainty of the cause of the leg pain as
well as the increase in spleen size. According to proto-
col this was not mandatory. The woman’s spleen vol-
ume returned to the baseline value, but the pain in her
legs persisted. 
After 12 months of low frequency therapy, patient n.
11 had a 14% increase in spleen volume compared to
baseline and an increase in liver ratio of 9%.
Interestingly, neither chitotriosidase nor QCSI values
changed significantly within this period of time. During
the study, the patient had skipped at least one infusion
because of problems with the intravenous access, which
may have caused the deterioration. Criteria for treat-
ment failure were not fulfilled and the study regimen
was continued. Six months later his liver ratio and
spleen volume had almost returned to baseline values,
again without changes in chitotriosidase and QCSI val-
ues.  
Discussion
Despite the tremendous success of ERT for Gaucher
disease type I, lifelong intravenous administration is bur-
densome for most patients. Several strategies for achiev-
ing greater convenience for patients have been consid-
ered. Home treatment with ERT has proven to be safe
and feasible, specifically by creating more flexibility.23
Substrate reduction (miglustat, Zavesca®, Actelion, Basel,
Switzerland) offers an oral alternative, although its use is
limited to patients who have mild to moderate disease
and who are unsuitable to receive ERT.24,25 Its value as
maintenance therapy after stabilization on ERT is current-
ly being studied. Decreasing the frequency of administra-
tion of ERT was proposed more then a decade ago for
patients with minimal disease symptoms after initial ther-
apy.26 In a recent consensus statement from the
International Collaborative Gaucher Group, it is recom-
mended that dose adjustments for maintenance therapy
should be made on an individual basis, but no monthly
administration schedules are included.27 In an uncon-
trolled study, signs and symptoms of disease worsened on
a monthly schedule, but patients had unstable and signif-
icant residual disease at the time treatment was changed
and a reduced cumulative dose was given.11 Drug holidays
to alleviate the burden of intravenous therapy do not
seem to be very successful. Grinzaid et al. withdrew four
patients from ERT for 1-7 years. All showed deterioration
in hematologic and visceral parameters, and in three
patients ERT had to be reinstituted.28 Elstein suggested
that adult patients with stable disease could be with-
drawn from ERT for circumscribed periods. However, of
the 15 patients who withdrew from ERT for an average
of 26 months (range 8-47), six had to restart therapy
because of deterioration of clinical features.29
Our study, in patients with stable and minimal residual
disease following ERT, is the first prospective randomized
trial of a maintenance regimen in which total dosage was
unchanged but frequency of drug administration was
reduced to once every 4 weeks. Although there were no
significant mean differences in any of the end-points
between the control and test arms, treatment failed in
two patients in the low frequency group, whereas all
patients in the control group remained stable. One patient
from the low frequency group did not want to continue
the study regimen because of subjective complaints,
although she did not meet the criteria of treatment failure.
The patients randomized to low frequency maintenance
ERT had more severe disease at baseline, evidenced by a
trend towards a higher SSI and liver ratio, significantly
larger spleens and the need for a higher treatment dose
compared to the control group. This may have influenced
the number of failures in this group. 
When taking a closer look at the patients in the low fre-
quency group whose disease progressed, patient #7 had a
slow decrease in QCSI as well as an increase in liver ratio,
and patient #9 had a decrease in QCSI, with other param-
eters remaining stable. In both patients, the deterioration
in these parameters represented an increase in Gaucher
cell mass.30-32 After reinstitution of the original treatment
regimen, both patients showed improvements. Although
the two patients in whom low-frequency treatment failed
did not have the worst composite disease severity either
before the initiation of ERT or at the start of the study, nor
had they received the lowest cumulative dose of treat-
ment, it is important to note that these patients had the
lowest baseline QCSI of all patients in the low frequency
group. Of interest is the fact that deterioration was not
always reflected in all parameters at the same time or to
the same extent. Only liver and spleen volume changes
showed a strong correlation with each other. These
observations emphasize the importance of adequate fol-
low-up of all parameters, including assessment of bone
marrow infiltration, because deterioration in this com-
partment is not always reflected by concomitant changes
in other parameters. The sensitivity of disease markers as
predictors of deterioration and the correlation between
the different parameters needs more study.
It should be noted that in many patients worldwide,
the average monthly ERT maintenance dose is usually
higher than that used in our study. Whether this higher
dose results in better maintenance of disease control also
needs further study. 
In conclusion, maintenance therapy, using a schedule of
ERT once every 4 weeks in adult Gaucher type I patients,
is feasible for some patients with stable and minimal
residual disease. It is likely that patients with a relatively
low baseline lumbar fat fraction may be at risk of disease
progression with less frequently administered ERT. It is
important to monitor all disease parameters closely for
early detection of disease progression and to adjust the
dosing frequency accordingly. 
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